Skip to main content

Refine your results

Filters

Displaying 2041 - 2060 of 2316

Public Statement

Improving the Economic Foundations of Competition Policy

Date
* This speech reflects the views of Chairman Muris and not necessarily those of the Commission or of any other Commissioner. Introduction I am delighted to speak at a symposium dedicated to my teacher...
Sep09
Event

Workshop on Health Care and Competition Law and Policy

-
The FTC held a public workshop on the implications of competition law and policy for health care financing and delivery. The workshop considered the impact of competition law and policy on the cost...
Cases and Proceedings

Physician Integrated Services of Denver, Inc., Michael J. Guese, M.D., and Marcia L. Brauchler

A consent order settled charges that a Denver, Colorado physician organization and its members, its president, Dr. M. J. Guese, and its non-physician consultant, M. A. Brauchler, increased fees for services through collective boycotts and agreements in a effort to fix the prices they would receive from health care insurance payers. The order prohibits the organization and its members and other respondents from entering into any agreement with insurance payers or providers to negotiate on behalf of the physicians group.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
0110173
Cases and Proceedings

Aurora Associated Primary Care Physicians, L.L.C., Richard A. Patt, M.D., Gary L. Gaede, M.D., and Marcia L. Brauchler

A consent order settled charges that the organization of internists, pediatricians, family physicians and general practitioners in the Aurora, Colorado area engaged in boycotts and entered into collective negotiations with health care insurers in an effort to increase the costs of physician services. The order prohibits the organization from entering into any agreement with insurance payers or providers to negotiate fees on behalf of the physicians group.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
0110174
Cases and Proceedings

Biovail Corporation

The Commission charged Biovail Corporation with illegally acquiring an exclusive patent license for Tiazac, a pharmaceutical used to treat high blood pressure and chronic chest pain. The complaint further alleged that Biovail, in an effort to maintain its monopoly, wrongfully listed the acquired license in the U.S. Food and Drug Administration’s “Orange Book” for the purpose of blocking generic competition to its branded Tiazac. The consent order requires Biovail to divest part of its exclusive rights to DOV; prohibits the firm from taking any action that would trigger additional statutory stays on final FDA approval of a generic form of Tiazac; and also prohibits Biovail from wrongfully listing any patents in the Orange Book for a product for which the company already has an New Drug Application from the FDA.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
011 0094
Docket Number
C-4060

Displaying 2041 - 2060 of 2316

Return to top